Lantheus Announces Presentations Featuring PYLARIFY® (Piflufolastat F18), PYLARIFY AI™ and NM-01 (PD-L1 Imaging) at the 2022 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual. Develop and deploy marketing strategies to drive ROI, sales and margin. The company believes the approval of a PSMA-targeted therapeutic for the treatment of adult patients with PSMA-positive metastatic castration. 1-800-299-3431. 47, as compared to $0. NEW YORK, Feb. [Image courtesy of Lantheus] Lantheus is a developer of AI-powered diagnostic and therapeutic products. 肿瘤学放射性药物 （帮助医疗保健专业人员发现、治疗和跟踪癌症的诊断和治疗方法）： ·PYLARIFY（也被称为Piflufolastat F-18、18F-DCFPyL或PyL）是一. COMPANY IDENTIFICATION: Progenics Pharmaceuticals, Inc. 52%) were up 21. PYLARIFY AI is an FDA-cleared artificial intelligence platform developed to assist in standardized quantification of PSMA PET/CT scans. PYLARIFY (piflufolastat F18) injection. Lantheus presented study results providing independent validation of PYLARIFY AI , the Company s artificial intelligence (AI) platform developed to assist in standardized quantification of PSMA PET/CT scans. The device provides general. “2022 was an outstanding year for Lantheus, led by the success of PYLARIFY and expansion of our Radiopharmaceutical Oncology pipeline. Leading the way for Lantheus is PYLARIFY, which delivered sales of $210. 48 from the prior year period. C. “2022 was an outstanding year for Lantheus, led by the success of PYLARIFY and expansion of our Radiopharmaceutical Oncology pipeline. By Kate Stalter • Oct 28, 2022LNTH earnings call for the period ending September 30, 2021. February 16, 2023 at 8:30 AM EST. Lantheus Announces Updates to the NCCN Guidelines for PSMA PET Imaging for Prostate Cancer. , a Lantheus company . May 27, 2021 — Today, the FDA approved the 18F-DCFPyL PSMA PET imaging agent (also known as “PyL” for short or by its trade name “PYLARIFY”). 5 million for the first quarter 2023. , Lantheus was founded in 1956 and formerly owned by Bristol Myers. S. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging. . “The data we presented at ASCO GU emphasize the clinical utility of piflufolastat F 18 to. , [18 F]-DCFPyL was approved by the Food and Drug Administration (FDA) in May 2021 and is commercially available as PYLARIFY ® (Piflufolastat F 18 Injection) and sold by Lantheus. In the U. 45%. PYLARIFY is the first and only commercially available, FDA-approved PSMA-targeted PET imaging agent for prostate cancer. In the second full quarter for both products in the market, PYLARIFY -- Lantheus -- reported $35. Lantheus experienced tremendous growth in last 2 years thanks to the approval of a new imaging agent called PYLARIFY. Progenics Pharmaceuticals, Inc. PYLARIFY AI is the first and only FDA-cleared Artificial Intelligence-Enabled PSMA – a truly game-changing product. February 10, 2022 17:33 ET | Source: Lantheus Holdings, Inc. Lantheus market research and analysis with ordering physicians, NCCN, ACS, UpToDate, SEER. PYLARIFY will be available immediately to imaging centers in parts of the mid-Atlantic and southern regions and is expected to be broadly available throughout the U. Lantheus has offices in Massachusetts, New Jersey, Canada and Sweden. S. 00. Lantheus Reports First Quarter 2023 Financial Results. Phone: 800-343-7851 Press Option 2 for Adverse Events and/or for Product Quality Complaints. 0. com. As the levels of PSA in your blood go up, a PYLARIFY PET/CT scan is better able to identify. 1 million for the second quarter 2023, compared to GAAP net income of $43. 24%) Q2 2021 Earnings Call. PYLARIFY, approved by the FDA in May 2021, is the first commercially and widely available prostate-specific membrane antigen (PSMA) PET imaging agent. PYLARIFY (piflufolastat F 18) injection (also known as 18 F-DCFPyL or PyL) is a fluorinated small molecule PSMA-targeted PET imaging agent that enables visualization of lymph nodes, bone and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. The company also received a CE marking in Europe for PYLARIFY AI. “We believe that PYLARIFY AI could enhance the efficient integration of PSMA PET/CT into clinical practice and will be. • Dispose of any unused PYLARIFY in compliance with applicable regulations. (the Company) (NASDAQ: LNTH), a company committed to“Lantheus is a demonstrated commercial leader in the field of radiopharmaceuticals. 9% sodium chloride injection USP. PYLARIFY AI is an FDA-cleared artificial intelligence platform developed to assist in standardized quantification of PSMA PET/CT scans. NORTH BILLERICA, Mass. GAAP. “The data we presented at ASCO GU emphasize the clinical utility of piflufolastat F 18 to. S. S. 3 million for the third quarter 2022, representing an increase of 134. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; PYLARIFY AI™, an artificial intelligence platform. Lantheus Holdings, Inc. Worldwide revenue of $239. Pylarify (piflufolastat), which was approved in 2021 by the Food and Drug Administration, is a. Lantheus Holdings (LNTH) announced Thursday that it would discontinue production and promotion of its FDA-approved radiotherapeutic Azedra. S. CC-BY-4. GAAP. , Sept. 4% from the prior year period ; GAAP net income of $61. PYLARIFY AI is an FDA-cleared artificial intelligence platform developed to assist in standardized quantification of PSMA PET/CT scans. BEDFORD, Mass. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider committed to innovative imaging diagnostics. patents apply to our products: DEFINITY ® /DEFINITY. 01. As part of the agreement with Novartis, Lantheus will provide PYLARIFY for the selection of patients with prostate cancer and Novartis will provide all PYLARIFY related clinical imaging data to Lantheus. with suspected recurrence based on elevated serum levels of prostate-specific antigen (PSA) level. #Lantheus was thrilled to be a Gold Sponsor of the 16th Clinical Trials on Alzheimer’s Disease conference (CTAD), which took place from Oct 24-27 in Boston! It was a wonderful opportunity to connect with our partners in the industry and academia who are using our investigational Tau PET imaging agent in their clinical trials. Under a commercial supply agreement with Lantheus, SOFIE will roll out PYLARIFY via its national network, which has manufactured numerous PYLARIFY doses for Lantheus during the clinical trials. The outlook from management for Pylarify growth was not what analysts -- who are are modeling this product out 2-3 years -- were expecting. Please enter your ZIP code to locate the nearest imaging site that offers PYLARIFY®. Since then, Lantheus' sales have more than doubled. 1 million for the third quarter of 2021, representing an increase of 134. Lantheus Announces Top Rated Oral Presentation Featuring PYLARIFY AI™ at the 2023 European Association of Nuclear Medicine (EANM) Annual Meeting. FDA Approval of PYLARIFY® (piflufolastat F 18) Injection, the First and Only Commercially Available PSMA PET Imaging Agent for. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging. Lantheus Receives U. MarketBeat Follows Only 4 people have added Lantheus to their MarketBeat. Lantheus también está trabajando en el desarrollo de productos para otros tipos de cáncer, como los tumores neuroendocrinos, y en el diagnóstico y estadificación de la. istering PYLARIFY. with suspected recurrence based on elevated serum levels of prostate-specific antigen (PSA) level. S. We accelerated our growth. NORTH BILLERICA,. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative. U. The PyLAM is the primary customer facing Lantheus Holdings professional tasked with education of the Prostate Cancer medical referral community on PyLARIFY and the cultivation of productive customer relationships to include HCPs, Advanced Practice Providers, Nurses, Pharmacists, Department Administrators and other key medical and. U. 01, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. “Lantheus delivered another strong quarter and full year, highlighted by revenue performance which increased 38% and 25%, respectively,” said Mary Anne Heino, President and CEO. This indicates a strong confidence in Pylarify’s growth, even amidst new. Lantheus’ product, PYLARIFY ® (piflufolastat F 18) injection, is a radioactive diagnostic agent indicated for PET imaging of PSMA positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy and/or with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. November 3, 2022 at 7:00 AM · 11 min read. 8M of net sales while cardiovascular ultrasound enhancement. It is used to determine the presence or absence of recurrent or metastatic prostate cancer. FDA Approval of PYLARIFY® (piflufolastat F 18) Injection, the First and Only Commercially Available PSMA PET Imaging Agent for Prostate Cancer. Melissa Downs Senior Director, Corporate Communications 646. Lantheus Presents Results from a PYLARIFY AI™ Study at the American Urological Association (AUA) Annual Meeting. This page is intended to serve as notice under 35 U. Assay the dose in a suitable dose calibrator prior to administration. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; TechneLite ® (Technetium Tc99m Generator), a. PYLARIFY injection is a fluorinated small molecule PSMA-targeted PET imaging agent that enables visualization of lymph nodes, bone and soft tissue metastases to determine the presence of recurrent and/or metastatic prostate cancer. , Lantheus received approval for [18 F]-DCFPyL, now PYLARIFY® (Piflufolastat F 18 Injection) from the Food and Drug Administration (FDA) in May 2021. Lantheus Receives U. PYLARIFY is the first and only commercially available, FDA-approved PSMA-targeted PET imaging agent for prostate cancer. FDA Approval of PYLARIFY® (piflufolastat F 18) Injection, the First and Only Commercially Available PSMA PET Imaging Agent for Prostate Cancer May 27, 2021 PYLARIFY will be available immediately to imaging centers in parts of the mid- Atlantic and southern regions and is expected to be broadly available Lantheus delivered a BIG and welcome beat-and-raise quarter and shares were up as much as +20%, poking their nose over $71. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging. 7 million for the second quarter 2023, representing an increase of 43. U. Lantheus Receives U. Follow. Lantheus’ product, PYLARIFY ® (piflufolastat F 18) injection, is a radioactive diagnostic agent indicated for PET imaging of PSMA positive lesions in men with prostate cancer: with suspected. 3% over the prior year. , [18F]-DCFPyL was approved by the FDA in May of 2021 and is commercially available as PYLARIFY® (Piflufolastat F 18 Injection) and sold by Lantheus. S. EMERGENCY PHONE: CHEMTREC 1-800-424-9300. 5 million, representing 61. PYLARIFY AI™ (aPROMISE) is the only deep learning enabled FDA-cleared medical device software to offer standardized PSMA PET reporting on PSMA PET/CT images, including those achieved using. , June 12, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. 3. S. D. price-eps-surprise | Lantheus Holdings, Inc. , Nov. November 29, 2021 08:30 ET | Source: Lantheus Holdings, Inc. , Professor of Urology, University of California San DiegoLantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging. “Lantheus delivered another strong quarter and full year, highlighted by revenue performance which increased 38% and 25%, respectively,” said Mary Anne Heino, President and CEO. 3% from the prior year period. • Dispose of any unused PYLARIFY in compliance with applicable regulations. 9% sodium chloride injection USP. c/o Lantheus Holdings 331 Treble Cove Road Billerica, MA 01862 United States of America 1-800-299-3431 . Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY®, a PSMA PET imaging agent. Melissa Downs Senior Director, Corporate Communications 646. It is worth mentioning that PYLARIFY is an F 18-labelled PSMA-targeted. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging. and EXINI Diagnostics AB. 22, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. Efficacy: High-risk PCa: OSPREY COHORT A; Efficacy: Biochemically Recurrent PCa: CONDOR; Efficacy:. Lantheus Receives U. Jul. 9% Sodium Chloride Injection USP. Lantheus Holdings. (“Progenics”), a Lantheus company, does not recommend or endorse any site included in the PYLARIFY® Imaging Site Locator for any purpose. MD, vice president of Medical Affairs at Lantheus, the developer of piflufolastat F 18, stated in a press release. , Progenics Pharmaceuticals, Inc. 9% Sodium Chloride Injection, USP. S. PYLARIFY is the first and only commercially available, FDA-approved PSMA-targeted PET imaging agent for prostate cancer. Lantheus Holdings, Inc. Based in North Billerica, Mass. PYLARIFY® [package insert]. PYLARIFY® FOR PCa IMAGING; EFFICACY AND SAFETY. . (“Lantheus”) (NASDAQ: LNTH), a company committed to improving. 5 million, representing 61. Patient-Level, Region-Matched Performance of PYLARIFY PET for Detection of Pelvic Lymph Node Metastasis in Trial 1 (n=252). Worldwide revenue of $263. Residents Only. Lantheus Holdings markets a fluorine-18 (F18) PSMA PET imaging product called Pylarify, for instance, which was approved last year. Lantheus (LNTH) stock rose ~17% on Thursday after Q4 results beat estimates and the FY23 outlook was placed above expectations. GAAP net. S. 3% over the prior year. “In addition to FDA approval, inclusion in the guidelines. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, announced today that the U. Enrollment and participation is free, and does not impose any requirements on the manner in which the facility provides service to patients. Lantheus Announces Top Rated Oral Presentation Featuring PYLARIFY AI at the 2023 European Association of Nuclear Medicine (EANM) Annual Meeting September 1, 2023 at 8:30 AM EDT BEDFORD, Mass. , [18 F]-DCFPyL was approved by the FDA in May of 2021 and is commercially available as PYLARIFY ® (Piflufolastat F 18 Injection) and sold by Lantheus. diagnostic radiopharmaceutical. In the U. North Billerica, MA: Progenics Pharmaceuticals, Inc. 17%. PYLARIFY AI is an FDA-cleared medical device software and is commercially available in the United States. Hours: 8:30 am to 8:00 pm ET, Monday to Friday. April 29, 2022 07:07 ET | Source: Lantheus Holdings, Inc. 48 from the prior year period. Do not use if it contains particulate matter or if it is discolored (PYLARIFY is a clear, colorless solution). Each CVR entitled its holder to receive a pro rata share of aggregate cash payments equal to 40% of U. Eastern Time. 4% from the prior year period. 22, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings. North Billerica, MA: Progenics Pharmaceuticals, Inc. PYLARIFY is the first and only commercially available, FDA-approved PSMA-targeted PET imaging agent for prostate cancer. Lantheus Holdings on Thursday reported Q4 adjusted net income of $1. (the Company) ( NASDAQ: LNTH ), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, announced it will present the following. GAAP net loss. PYLARIFY AI deployment can be facilitated both as a secure web cloud application and as a local. BEDFORD, Mass. Lantheus said its worldwide revenue for the period rose ~134% YoY to $239. S. Even if Bracco were to secure 40%+ share in an expanding F-18 PSMA PET imaging market over the next 3 years, the Truist team still thinks Pylarify and Lantheus are undervalued, especially with the. It describes its PYLARIFY injection as “a radioactive diagnostic agent indicated. In the last reported quarter, the company’s earnings of 97 cents per share. NORTH BILLERICA, Mass. and EXINI Diagnostics AB and anWorldwide revenue of $223. We accelerated our growth, diversified our portfolio, and delivered record revenues and profits which created additional free cash flows,” said Mary Anne Heino , President and Chief Executive Officer of. Worldwide revenue of $208. The Company’s worldwide revenue for the second quarter of 2022 totaled $223. ” Read more about PyL here and about the amazing science behind PSMA hereLantheus Holdings, Inc. “2022 was an outstanding year for Lantheus, led by the success of PYLARIFY and expansion of our Radiopharmaceutical Oncology pipeline. PYLARIFY –Prostate Cancer Franchise Overview Paul Blanchfield, Chief Commercial Officer Etienne Montagut, Chief Business Officer Aseem Anand, VP of Digital Solutions PYLARIFY Key Opinion Leader Panel Moderator: Bela Denes, M. , June 12, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. PYLARIFY may be diluted with 0. PYLARIFY® (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy. 47, as compared to $0. 2 million for the third quarter 2022, compared to GAAP net loss of $13. The problem for Point, a group that went public amid much fanfare as a Spac last year, is that investors. PYLARIFY was approved by the U. 0 million and $150. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; TechneLite ® (Technetium Tc99m Generator), a. PYLARIFY AI is an FDA-cleared medical device software and is commercially available in the United States. 9 mg ethanol in 0. Lantheus Announces Top Rated Oral Presentation Featuring PYLARIFY AI™ at the 2023 European Association of Nuclear Medicine (EANM) Annual Meeting. . EMERGENCY PHONE: CHEMTREC 1-800-424-9300. Lantheus Announces Presentations Featuring PYLARIFY AI™ at the 2023 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting. Lantheus Holdings, Inc. Indication PYLARIFY ® (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen. “Lantheus is leading the way in harnessing the power of AI and machine learning technologies, together with our game-changing PSMA-targeted PET imaging agent PYLARIFY, to potentially transform. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes. Intended for U. 3% over the prior. This agent is similar to the Gallium-68 PSMA-11 agent which was approved in December 2020, except that it can be produced in much greater quantities and distrMarketBeat has tracked 5 news articles for Lantheus this week, compared to 5 articles on an average week. Lantheus presented study results providing independent validation of PYLARIFY AI™, the Company’s artificial intelligence (AI) platform developed to assist in standardized quantification of. by year. PYLARIFY Injection is designed to detect prostate-specific membrane. 97 for the first quarter of 2022, representing an increase of approximately $0. • Calculate the necessary volume to administer based on calibration time and required dose. United States of America . The PyLAM is the primary customer facing Lantheus Holdings professional tasked with education of the Prostate Cancer medical referral community on PyLARIFY and the cultivation of productive customer relationships to include HCPs, Advanced Practice Providers, Nurses, Pharmacists, Department Administrators and other key medical and. 33 for the second quarter 2023, compared. “The transaction leverages Lantheus’. Global Data 3rd line treatment for metastatic castration-resistant prostate cancer (“mCRPC”), Lantheus primary market research informing imaging procedures performed during radioligand treatment. Each milliliter contains 37 to 2,960 MBq (1 to 80 mCi) piflufolastat F 18 with ≤0. 86 for the third quarter 2022, compared to. 50. commercial products, particularly PYLARIFY and DEFINITY, in the face of competition; (ii) our ability to have third parties manufacture our products and our ability to manufacture DEFINITY in our in-house. In the U. Novartis will include PYLARIFY® (piflufolastat F18) in their clinical trials for Pluvicto™ (lutetium Lu. Lantheus Announces Presentations Featuring PYLARIFY AI™ at the 2023 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting June 12,. Worldwide revenue of $129. 1% over the. In hindsight it appears that the sellside failed to appreciate Pylarify's potential. June 12,. Under. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging. Lantheus presented study results providing independent validation of PYLARIFY AI™, the Company’s artificial intelligence (AI) platform developed to assist in standardized quantification of PSMA PET/CT scans. 9% Sodium Chloride Injection, USP. , June 12, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. 2 million, compared with $129. Read More. is the parent company of Lantheus Medical Imaging, Inc. NORTH BILLERICA, Mass. "2022 was an outstanding year for Lantheus, led by the success of PYLARIFY and the expansion of our Radiopharmaceutical Oncology pipeline. Lantheus’ product, PYLARIFY, is a radioactive diagnostic agent indicated for PET imaging of PSMA positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy and/or with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. NEW YORK, Jan. and EXINI Diagnostics AB. 1 million for the third quarter 2021, representing an increase of 15. NORTH BILLERICA, Mass. For more information, visit Contacts: Mark Kinarney Vice President, Investor Relations 978-671-8842 ir@lantheus. , a Lantheus company . A sample CMS-1500 claim form for billing PYLARIFY® is provided below. Lantheus has multiple products on the market with two standouts driving the most growth with Pylarify and Definity. Paul joined Lantheus in 2020 and has been an exemplary leader throughout his tenure, demonstrating strong strategic and leadership skills, most notably with the very successful launch of PYLARIFY. For more information, visit Contacts: Mark Kinarney Vice President, Investor Relations 978-671-8842 ir@lantheus. "It's not like there is only one PSMA molecule that we can radiolabel," said Cameron Foster, director of theranostics at the University of California, Davis. m. 45 and $0. 7% year-over-year growth and approximately 8% sequential growth from the first quarter of 2023, with the vast majority of our sequential growth driven by our existing accounts. Frederic Pouliot, Hospitalier Universitaire (CHU) de Québec-Université Laval. PYLARIFY will be available immediately to imaging centers in parts of the mid- Atlantic and southern regions and is expected to be broadly available throughout the U. S. Risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements include: (i) continued market expansion and penetration for our established commercial products, particularly PYLARIFY and DEFINITY, in a competitive environment in which other imaging agents have been approved. “PYLARIFY has the potential to contribute meaningful and actionable information that can be used to personalize treatment plans in men with low PSA levels,” said Dr. , Nov. com. 97 for the first quarter of 2022, representing an increase of approximately $0. We obtained FDA approval for and successfully launched PYLARIFY®Lantheus will fund the all-cash license of exclusive worldwide rights, excluding certain territories 1, for PNT2002 and PNT2003 with cash on Lantheus’ balance sheet and committed financing. , Nov. , Nov. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY®, a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; PYLARIFY AI™, an artificial intelligence platform. Greater Chicago Area. Global Data 3rd line treatment for metastatic castration-resistant prostate cancer (“mCRPC”), Lantheus primary market research informing imaging procedures performed during radioligand treatment. 0. Now, with 2 PSMA PET radiotracers approved, this type of imaging will become more widely available for patients. All rights reserved. 54, as compared to $0. PYLARIFY may be diluted with 0. Lantheus will fund the all-cash license of exclusive worldwide rights, excluding certain territories 1, for PNT2002 and PNT2003 with cash on Lantheus’ balance sheet and committed financing. by year endNORTH BILLERICA, Mass. “The data we presented at ASCO GU emphasize the clinical utility of piflufolastat F 18 to. This sample claim form is only an example. S. 8 million for the first quarter 2023, representing an increase of 44. “PYLARIFY has the potential to contribute meaningful and actionable information that can be used to personalize treatment plans in men with low PSA levels,” said Dr. 29. “2022 was an outstanding year for Lantheus, led by the success of PYLARIFY and expansion of our Radiopharmaceutical Oncology pipeline. Lantheus Receives U. Image source: The Motley Fool. These developments underscore Lantheus’ efforts to establish PYLARIFY as a PSMA PET imaging agent of choice in the U. The Lantheus Protocol: Pylarify Growth May Slow The outlook from management for Pylarify growth was not what analysts -- who are are modeling this product out 2-3 years -- were expecting. S. “Lantheus is leading the way in harnessing the power of AI and machine learning technologies, together with our game-changing PSMA-targeted PET imaging agent PYLARIFY, to potentially transform the way that clinicians manage and treat prostate cancer,” said Jean-Claude Provost, MD, Interim Chief Medical Officer, Lantheus. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; TechneLite ® (Technetium Tc99m Generator), a. S. Billerica, MA 01862 . Today, we put the spotlight on Lantheus Holdings for the first time. Shares of Lantheus Holdings (LNTH-0. 8% from the prior year period. In patients with. In June, Lantheus announced that it has demonstrated the higher efficiency and consistency of the Pylarify AI platform while maintaining the diagnostic accuracy of Prostate-Specific Membrane. On the call, management stated that PYLARIFY and DEFINITY enabled Lantheus to invest in its business to continue to expand its portfolio of commercial and clinical-stage radiopharmaceutical assets. m. , a Lantheus company. Lantheus’ product, PYLARIFY ® (piflufolastat F 18) injection, is a radioactive diagnostic agent indicated for PET imaging of PSMA positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy and/or with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. Senior Director, Investor Relations. The approval covers the use of Lu177-PSMA-617 in patients who have metastatic prostate cancer that is hormone-resistant (also known as castrate-resistant) and whose. 3 million for the third quarter 2022, representing an increase of 134. 31 Mar, 2022, 09:00 ET. 2 million, compared with $129. PYLARIFY® Peer-to-Peer Reader Assistance Program is a complementary program to the PYLARIFY® Reader Training that provides guidance and assistance to healthcare providers on how to accurately read and interpret PYLARIFY® scans. , [18 F]-DCFPyL was approved by the FDA in May of 2021 and is commercially available as PYLARIFY ® (Piflufolastat F 18 Injection) and sold by Lantheus. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging. PYLARIFY ® (piflufolastat F 18) injection (also known as 18 F-DCFPyL or PyL) is a fluorinated small molecule PSMA-targeted PET imaging agent that enables visualization of lymph nodes, bone and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. Comparison of Gallium-68 and Fluorine-18 imaging characteristics in positron emission. (LNTH) 1 Like. PYLARIFY is the first and only commercially available, FDA-approved PSMA-targeted PET imaging agent for prostate cancer NORTH BILLERICA, Mass. m. Image source: The Motley Fool. PYLARIFY works with PET/CT technology to produce a combined PET/CT scan that enables the reader of the PET/CT scan to detect and locate the disease. 5 million for the first quarter 2023. GAAP net. INDICATION. PYLARIFY is used along with positron emission tomography (PET) imaging for men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy. S. 1 million for the second quarter of 2021, representing an increase of 121. S. 1 million in the prior year period; GAAP fully diluted net income per share of $1. PYLARIFY AI™ is intended to be used by healthcare professionals and researchers for acceptance, transfer, storage, image display, manipulation, quantification and reporting of digital medical images. On the call, management stated that PYLARIFY and DEFINITY enabled Lantheus to invest in its business to continue to. For more information, visit Contacts: Mark Kinarney Vice President, Investor Relations 978-671-8842 [email protected] has multiple products on the market with two standouts driving the most growth with Pylarify and Definity. (the Company) (NASDAQ: LNTH), a company committed to“PYLARIFY AI has the potential to contribute meaningful insights to inform treatment selection and monitoring in prostate cancer. PYLARIFY is the first and only commercially available, FDA-approved PSMA-targeted PET imaging agent for prostate cancer. Post Administration Instructions • Follow the PYLARIFY injection with an intravenous flush of 0. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; TechneLite ® (Technetium Tc99m Generator), a technetium-based generator. S. 47, as compared to $0. S. PYLARIFY Injection is designed to detect prostate-specific membrane. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; TechneLite ® (Technetium Tc99m Generator), a technetium-based generator. EMERGENCY PHONE: CHEMTREC 1-800-424-9300. Each CVR entitled its holder to receive a pro rata share of aggregate cash payments equal to 40% of U.